Glen B Taksler1,2,3, Phuc Le4, Bo Hu5, Jay Alberts6,7, Allen J Flynn8, Michael B Rothberg4. 1. Cleveland Clinic Community Care, Cleveland Clinic, 9500 Euclid Ave., G10, Cleveland, OH, USA. taksleg@ccf.org. 2. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. taksleg@ccf.org. 3. Population Health Research Institute, Case Western Reserve University at The MetroHealth System, Cleveland, OH, USA. taksleg@ccf.org. 4. Cleveland Clinic Community Care, Cleveland Clinic, 9500 Euclid Ave., G10, Cleveland, OH, USA. 5. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. 6. Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, USA. 7. Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. 8. School of Information and Department of Learning Health Sciences, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: The US Preventive Services Task Force recommends 25 primary preventive services for middle-aged adults, but it can be difficult to do them all. METHODS: The Personalized Disease Prevention (PDP) cluster-randomized clinical trial will evaluate whether patients and their providers benefit from an evidence-based decision tool to prioritize preventive services based on their potential to improve quality-adjusted life expectancy. The decision tool will be individualized for patient risk factors and available in the electronic health record. This Phase III trial seeks to enroll 60 primary care providers (clusters) and 600 patients aged 40-75 years. Half of providers will be assigned to an intervention to utilize the decision tool with approximately 10 patients each, and half will be assigned to usual care. Mixed-methods follow-up will include collection of preventive care utilization from electronic health records, patient and physician surveys, and qualitative interviews. We hypothesize that quality-adjusted life expectancy will increase by more in patients who receive the intervention, as compared with controls. DISCUSSION: PDP will test a novel, holistic approach to help patients and providers prioritize the delivery of preventive services, based on patient risk factors in the electronic health record. TRIAL REGISTRATION: ClinicalTrials.gov NCT05463887. Registered on July 19, 2022.
BACKGROUND: The US Preventive Services Task Force recommends 25 primary preventive services for middle-aged adults, but it can be difficult to do them all. METHODS: The Personalized Disease Prevention (PDP) cluster-randomized clinical trial will evaluate whether patients and their providers benefit from an evidence-based decision tool to prioritize preventive services based on their potential to improve quality-adjusted life expectancy. The decision tool will be individualized for patient risk factors and available in the electronic health record. This Phase III trial seeks to enroll 60 primary care providers (clusters) and 600 patients aged 40-75 years. Half of providers will be assigned to an intervention to utilize the decision tool with approximately 10 patients each, and half will be assigned to usual care. Mixed-methods follow-up will include collection of preventive care utilization from electronic health records, patient and physician surveys, and qualitative interviews. We hypothesize that quality-adjusted life expectancy will increase by more in patients who receive the intervention, as compared with controls. DISCUSSION: PDP will test a novel, holistic approach to help patients and providers prioritize the delivery of preventive services, based on patient risk factors in the electronic health record. TRIAL REGISTRATION: ClinicalTrials.gov NCT05463887. Registered on July 19, 2022.
Authors: Erin S Leblanc; Elizabeth O'Connor; Evelyn P Whitlock; Carrie D Patnode; Tanya Kapka Journal: Ann Intern Med Date: 2011-10-04 Impact factor: 25.391
Authors: Glen B Taksler; Melanie Keshner; Angela Fagerlin; Negin Hajizadeh; R Scott Braithwaite Journal: Ann Intern Med Date: 2013-08-06 Impact factor: 25.391
Authors: Geoffrey H Tison; Robert Avram; Peter Kuhar; Sean Abreau; Greg M Marcus; Mark J Pletcher; Jeffrey E Olgin Journal: Ann Intern Med Date: 2020-06-29 Impact factor: 25.391
Authors: Erika Rees-Punia; Christina C Newton; Melissa H Rittase; Rebecca A Hodge; Jannie Nielsen; Solveig Cunningham; Lauren R Teras; Alpa Patel Journal: BMJ Open Date: 2021-12-02 Impact factor: 2.692
Authors: Glen B Taksler; Bo Hu; Frederic DeGrandis; Victor M Montori; Angela Fagerlin; Zsolt Nagykaldi; Michael B Rothberg Journal: JAMA Netw Open Date: 2021-11-01